^
Association details:
Biomarker:No biomarker
Cancer:Oropharyngeal Cancer
Drug:Keytruda (pembrolizumab) (PD1 inhibitor) +
Erbitux (cetuximab) (EGFR inhibitor)
Direction:Sensitive
Evidence:
Evidence Level:
Sensitive: A2 - Guideline
Source:
Published date:
12/08/2021
Excerpt:
PRINCIPLES OF SYSTEMIC THERAPY FOR NON-NASOPHARYNGEAL CANCERS (Lip, Oral Cavity, Oropharynx, Hypopharynx, Glottic Larynx, Supraglottic Larynx, Ethmoid Sinus, Maxillary sinus, Occult Primary)...Useful in Certain Circumstances...Cetuximab/pembrolizumab